製品番号: HY-151978

ZC0109

カスタマーレビュー

Based on 1 Customer Validation

ZC0109 is a dual inhibitor of IDO1 and thioredoxin reductase 1 (TrxR1) with IC₅₀s of 50 nM and 3.0 μM, respectively. ZC0109 induces ROS accumulation and cell cycle arrest at G1/S phase, thus leads to cancer cells apoptosis.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.86%
CAS 番号: 3037850-79-3
分子式: C₂₂H₂₀BrFN₈O₄S
分子量:591.41

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

ZC0109 構造式

CAS 番号: 3037850-79-3

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

IC50: 50 nM (IDO1), 3.0 μM (TrxR1)^[1]

Indoleamine 2,3-Dioxygenase (IDO) アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
CT26	IC₅₀	12.4 μM Compound: 12d; ZC0109	Cytotoxicity against mouse CT26 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against mouse CT26 cells incubated for 48 hrs by CCK-8 assay	[PMID: 36370550]
HCT-116	IC₅₀	1.52 μM Compound: 12d; ZC0109	Cytotoxicity against TrxR1 knockdown human HCT-116 cells incubated for 24 hrs by CCK-8 assay (Rvb = 3.08 +/- 0.55 uM) Cytotoxicity against TrxR1 knockdown human HCT-116 cells incubated for 24 hrs by CCK-8 assay (Rvb = 3.08 +/- 0.55 uM)	[PMID: 36370550]
HCT-116	IC₅₀	1.67 nM Compound: 12d; ZC0109	Cytotoxicity against human HCT-116 cells transfected with TrxR1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 3.49 +/- 0.28 uM) Cytotoxicity against human HCT-116 cells transfected with TrxR1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 3.49 +/- 0.28 uM)	[PMID: 36370550]
HCT-116	IC₅₀	18.08 nM Compound: 12d; ZC0109	Cytotoxicity against IDO1 knockdown human HCT-116 cells incubated for 24 hrs by CCK-8 assay (Rvb = 36.50 +/- 3.20 nM) Cytotoxicity against IDO1 knockdown human HCT-116 cells incubated for 24 hrs by CCK-8 assay (Rvb = 36.50 +/- 3.20 nM)	[PMID: 36370550]
HCT-116	IC₅₀	3.33 μM Compound: 12d; ZC0109	Cytotoxicity against human HCT-116 cells incubated for 24 hrs CCK-8 assay Cytotoxicity against human HCT-116 cells incubated for 24 hrs CCK-8 assay	[PMID: 36370550]
HCT-116	IC₅₀	3.44 μM Compound: 12d; ZC0109	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay	[PMID: 36370550]
HCT-116	IC₅₀	3.44 μM Compound: 12d; ZC0109	Cytotoxicity against human HCT-116 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HCT-116 cells incubated for 48 hrs by CCK-8 assay	[PMID: 36370550]
HCT-116	IC₅₀	3.79 μM Compound: 12d; ZC0109	Cytotoxicity against human HCT-116 cells transfected with IDO1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 3.49 +/- 0.28 uM) Cytotoxicity against human HCT-116 cells transfected with IDO1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 3.49 +/- 0.28 uM)	[PMID: 36370550]
HCT-116	IC₅₀	60.83 μM Compound: 12d; ZC0109	Cytotoxicity against human HCT-116 cells incubated for 24 hrs in presence of NAC CCK-8 assay Cytotoxicity against human HCT-116 cells incubated for 24 hrs in presence of NAC CCK-8 assay	[PMID: 36370550]
HeLa	IC₅₀	10.09 μM Compound: 12d; ZC0109	Cytotoxicity against human HeLa cells transfected with IDO1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 9.74 +/- 1.64 uM) Cytotoxicity against human HeLa cells transfected with IDO1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 9.74 +/- 1.64 uM)	[PMID: 36370550]
HeLa	IC₅₀	10.2 μM Compound: 12d; ZC0109	Cytotoxicity against human HeLa cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HeLa cells incubated for 48 hrs by CCK-8 assay	[PMID: 36370550]
HeLa	IC₅₀	16.08 μM Compound: 12d; ZC0109	Cytotoxicity against human HeLa cells incubated for 24 hrs CCK-8 assay Cytotoxicity against human HeLa cells incubated for 24 hrs CCK-8 assay	[PMID: 36370550]
HeLa	IC₅₀	26.13 μM Compound: 12d; ZC0109	Cytotoxicity against IDO1 knockdown human HeLa cells incubated for 24 hrs by CCK-8 assay (Rvb = 45.93 +/- 2.23 nM) Cytotoxicity against IDO1 knockdown human HeLa cells incubated for 24 hrs by CCK-8 assay (Rvb = 45.93 +/- 2.23 nM)	[PMID: 36370550]
HeLa	IC₅₀	4.86 μM Compound: 12d; ZC0109	Cytotoxicity against human HeLa cells transfected with TrxR1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 9.74 +/- 1.64 uM) Cytotoxicity against human HeLa cells transfected with TrxR1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 9.74 +/- 1.64 uM)	[PMID: 36370550]
HeLa	IC₅₀	7.2 μM Compound: 12d; ZC0109	Cytotoxicity against TrxR1 knockdown human HeLa cells incubated for 24 hrs by CCK-8 assay (Rvb = 13.79 +/- 2 uM) Cytotoxicity against TrxR1 knockdown human HeLa cells incubated for 24 hrs by CCK-8 assay (Rvb = 13.79 +/- 2 uM)	[PMID: 36370550]
HeLa	IC₅₀	74.15 μM Compound: 12d; ZC0109	Cytotoxicity against human HeLa cells incubated for 24 hrs in presence of NAC CCK-8 assay Cytotoxicity against human HeLa cells incubated for 24 hrs in presence of NAC CCK-8 assay	[PMID: 36370550]

体外実験

ZC0109 (24 h) inhibits cancer cells with IC₅₀s of 3.44 μM (HCT-116), 12.4 μM (CT26), and 10.2 μM (HeLa), respectively^[1].
ZC0109 (2.5-10 μM; 24 h) induces ROS accumulation in HCT-116 and HeLa cells^[1].
ZC0109 (2.5-10 μM; 24 h) induces apoptosis and G1/S cell cycle arrest in cancer cell^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:

HCT-116 cells and HeLa cells
Concentration:

2.5 μM, 5 μM, and 10 μM
Incubation Time:

24 hours
Result:

Arrested cell cycle at G1/S phase.

体内実験

ZC0109 (15, 30, and 60 mg/kg; p.o.; once daily for 28 d) reduces Kyn/Trp metabolism in C57BL/6 mice^[1].
ZC0109 (60 mg/kg; p.o.; once daily for 28 d) decreases tumor growth and increases accumulation and infiltration of T cells in CT-26 cells transplanted immunocompetent BALB/c mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 3037850-79-3
性状 Solid
分子量 591.41
分子式 C₂₂H₂₀BrFN₈O₄S
Color White to off-white
SMILES

O/N=C(C1=NON=C1NCCCC2=NN=C(S2)NC(CC3=CC=C(C=C3)O)=O)\NC4=CC(Br)=C(C=C4)F
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (84.54 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6909 mL

8.4544 mL

16.9087 mL

5 mM

0.3382 mL

1.6909 mL

3.3817 mL

10 mM

0.1691 mL

0.8454 mL

1.6909 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (274 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Zhou J, et al. Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114860. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6909 mL	8.4544 mL	16.9087 mL	42.2719 mL
	5 mM	0.3382 mL	1.6909 mL	3.3817 mL	8.4544 mL
	10 mM	0.1691 mL	0.8454 mL	1.6909 mL	4.2272 mL
	15 mM	0.1127 mL	0.5636 mL	1.1272 mL	2.8181 mL
	20 mM	0.0845 mL	0.4227 mL	0.8454 mL	2.1136 mL
	25 mM	0.0676 mL	0.3382 mL	0.6763 mL	1.6909 mL
	30 mM	0.0564 mL	0.2818 mL	0.5636 mL	1.4091 mL
	40 mM	0.0423 mL	0.2114 mL	0.4227 mL	1.0568 mL
	50 mM	0.0338 mL	0.1691 mL	0.3382 mL	0.8454 mL
	60 mM	0.0282 mL	0.1409 mL	0.2818 mL	0.7045 mL
	80 mM	0.0211 mL	0.1057 mL	0.2114 mL	0.5284 mL

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

ZC0109

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Indoleamine 2,3-Dioxygenase (IDO) アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

ZC0109

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Indoleamine 2,3-Dioxygenase (IDO) アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

ZC0109 関連分類

HY-151978 関連分類